ArticleJournal of thoracic disease2026
Post-operative outcomes of lung resection after perioperative chemoimmunotherapy for stage IIB-IIIB non-small-cell lung cancer in the elderly: a single center real-life experience.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Locally advanced non-small cell lung cancer (LA-NSCLC) needs a multidisciplinary management and patients undergoing an intentional to treat pathway have also a high risk of recurrence even after neoadjuvant chemotherapy followed by curative resection. Recently, perioperative chemoimmunotherapy (CIO) changed the treatment paradigm. However, literature is lacking in the comparison of the post-operative outcomes in elderly patients. The aim of this study was to assess the post-operative results of perioperative CIO in patients aged ≥70 years. Methods: We conducted a single-center retrospective analysis on patients with clinical stage IIB-IIIB NSCLC who underwent treatment between January 2015 and June 2025. We compared post-operative outcomes of patients who received perioperative CIO with a control group of patients who received standard chemotherapy stratifying the study population focusing on elderly patients. Results: In the study period we identified 174 patients with stage IIB-IIIB NSCLC underwent lung surgery after standard chemotherapy (n=121) or CIO (n=53) and among these elderly represented 42.9% and 32.1% respectively. Ninety-day mortality was 2.4% Conclusions: Lung resection after perioperative CIO is feasible and safe even in elderly patients, without major or life-threatening complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.